Results of SHARP Study

Chest

Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP)

We evaluated solriamfetol’s effect on cognitive function in patients with obstructive sleep apnea and excessive daytime sleepiness. In this randomized crossover trial of 59 participants, solriamfetol significantly improved cognitive performance (DSST; effect size 0.37) compared to placebo, with consistent improvements in subjective cognition, sleepiness, and global severity.

Leary EB*, Van Dongen HPA*, Drake C, Bogan R, Jaeger J, Rosenberg R, Streicher C, Tabuteau H. Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP): A Randomized Placebo-Controlled Double-Blind Repeated-Measures Crossover Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in OSA With Excessive Daytime Sleepiness and Cognitive Impairment. Chest. 2024 Nov 9: S0012-3692(24)05470-9. DOI: 10.1016/j.chest.2024.10.050. Epub ahead of print. PMID: 39528111. (* equal contribution)

Peer Reviewed ArticlesEileen LearyCV